20th October 2020 - Alerts roundup |
Find all of CBD-Intel’s coronavirus-related regulatory alerts here, updated as they appear
The CBD-Intel Health hub presents developments related to the science behind CBD and health.
Find all of CBD-Intel’s coronavirus-related regulatory alerts here, updated as they appear
There are still quite a few unanswered questions regarding the novel food application process under the FSA. Fortunately the requirement of having toxicological data
Commercial interest in mushrooms as active ingredients is on the rise – despite legal issues that severely curtail commercial opportunities
CBD-Intel’s newly upgraded global regulatory tracker, updated every month, now offers a deeper analysis of each regulatory area.
Use the tabs at the top of the map to select a specific regulatory field and click on an individual country to bring up much more detail in the panel below, including links to legislation and CBD-Intel’s coverage of that market.
The key below the map indicates the level of regulation for the selected country and regulatory field based on our in-house analysis.
Increasing numbers of CBD businesses are marketing products that chime with the wellness trend and now even Playboy is launching a line of CBD products in the US that promise physical and mental benefits
Maria Alejandra Estanga, our market analysts, presented the current status of the topicals market across the most important CBD markets during the Virtual Cannacosmo Health + Beauty Expo on 29st September.
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
Studies looking at the potential for CBD to treat or alleviate COVID-19 symptoms continue to progress – with one study hinting at promising results combining CBD with other terpene products
The pharmaceutical side of the cannabinoid industry continues to grow, with several major announcements expanding treatments and blurring boundaries
CBD-Intel managing director, Tim Phillips, discusses the main facts and issues surrounding CBD and Novel Food status in European markets. He presents the key aspects of the delay, the political issues and the impacts released on the European level and the future challenges for the sector.
The bankruptcy stories continue for cannabinoid firms in the US and Canada as businesses struggle to survive in turbulent times
Expansion plans by two major players suggest confidence in the future of the CBD market in the UK, with one anticipating a continuing rise in sales driven by reactions to the COVID-19 pandemic
A comprehensive list of possible cannabinoid/drug interactions has been published for the first time by researchers at Penn State University in the US
Canopy, the Canadian cannabinoid company, has continued to commit heavily to BioSteel, a sports nutrition company in which Canopy now owns the majority share.
Canadian cannabinoid firm Canopy Growth has signed a multi-year deal with NFL quarterback Patrick Mahomes as part of its advance into the sports nutrition market
New research into the therapeutic potential of lesser known cannabinoids is progressing with recent discoveries about a host of new compounds
Registration in the US FDA National Drug Code (NDC) Directory conveys significant benefits even if the FDA does not specifically approve these items as over-the-counter products, according to a CBD company
The FDA’s recent report that fewer than half of the CBD products tested from US store shelves contain the amount of CBD on the label was unwelcome news
A proposed new path forward and extra information presented by Zynerba Pharmaceuticals has thus far not impacted the company’s stock price
Enforcement activity against food, drink and dietary supplement products placed on the market containing CBD continues despite the inability of companies to proceed with novel food applications due to the EC’s questions over whether CBD constitutes a narcotic under the 1961 UN Single Convention on Narcotics.
Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.
The use of CBD-based products has reduced the consumption of prescription drugs in Italy, according to a discussion paper from an international economics think-tank
Subscription services are a niche area of the CBD market that could benefit from the ongoing COVID-19 pandemic, providing companies with security and customers with a way to try new products without leaving home
There is some scientific evidence that CBD could encourage smoking cessation and have significant health benefits for those struggling to give up cigarettes
A CBD oil made by Brazilian drugs company Prati-Donaduzzi could become the biggest-selling cannabinoid product on the Brazilian market
Initial reports on the results of the first ever socially distanced 4/20 are a mixed bag
In order to help you keep track of how all this is affecting the CBD industry around the world, all CBD-Intel’s COVID-19-related coverage can now be found in one place here
A new national committee is to be set up in Canada to study all aspects of non-prescription cannabis health products, including CBD products
CBD entrepreneur Christina DiArcangelo tells CBD-Intel that businesses should be using the slowdown to study, reflect, plan – and “get ahead of the ball”
The wider impact of COVID-19 on the CBD sector in the US remains confused in the short term and largely a mystery in the longer term as companies scramble to gather information
Liver toxicity is not really an issue for CBD, but questions remain about its efficacy and how it may affect the efficacy of other drugs. That’s according to leading cannabinoids researcher Kent Vrana
Industry organisations have responded in anger to continued claims being made by some companies about the supposed power of cannabinoids in tackling COVID-19
Also: GW suggests another possible use for Epidyolex; Lawsuit alleges hemp plants were contaminated with pesticide; Elixinol rebrands to move away from medicinal image; Kentucky hemp business goes bust
Bogus claims that products containing CBD may have any beneficial effects in treating or warding off coronavirus risk the wrath of authorities in the US – and could ultimately damage CBD’s reputation
As the COVID-19 pandemic continues to affect people across the world, a swathe of CBD-related events have been called off or postponed. Here is a list of some of the major ones, with dates and details
Unclear testing standards for CBD oil in the UK have led to uncertainty over test results on THC and CBD content for many popular CBD products
Results from a successful phase three clinical trial on the use of Epidiolex to treat drug-resistant Dravet syndrome have been published in the JAMA Neurology journal
A company is looking to use broader evidence permissions to provide the US Food and Drug Administration (FDA) with data on CBD and liver toxicity
Toothpaste giant Colgate is entering the CBD market, researchers have created a laser scanner that can tell the difference between legal hemp and potentially illegal cannabis, and wrestling legend Kevin Nash has become the latest celebrity to endorse CBD, plus more
TobaccoIntelligence, a new service from the team that produces CBD-Intel, is now available, covering the global tobacco and nicotine alternatives sector
Germany’s Federal Institute for Risk Assessment (BfR) recently issued a warning on e-liquids that it believed to be containing synthetic cannabinoids, after at least eight teenagers suffered medical complications from an as yet unconfirmed source
Tom Hanks refutes false claims over endorsement of CBD products, research suggests cannabinoids benefit gene receptor diseases and CBD coffee is set to hit the market, plus more
Peru is moving towards comprehensive legislation on cannabis but has yet to define how to classify CBD, leaving the guidelines unworkable for now
A US-based hemp research firm is working with a university in Florida to create an FDA-approved capsule that could replicate the painkilling abilities of ibuprofen
Two new studies have shown hopeful signs that CBD could be combined with existing drugs to improve treatment – in one case, of cancer, and in the other of the potentially deadly E. coli
As more victims of Parkinson’s disease turn to CBD to relieve symptoms such as tremors, anxiety and insomnia, Parkinson’s UK is investing in a clinical trial into how CBD might benefit those suffering Parkinson’s-related psychosis
The CBD sports topicals sector has grown significantly in the last year, with many UK high street retailers now stocking CBD massage oils and recovery balms
Regulation in Belgium and possibly across Europe may change as a result of the link being made between CBD vaping and a teenager’s death – though that link has not been verified
The Irish government has given approval to two CBD-based medicines as it starts its medical cannabis programme
The organisers of Hemp and CBD Expo invited our MD, Tim Phillips, to participate in their round table about Brexit. Their aim was to objectively understand what the Brexit impacts are going to be over the next few years for CBD and the UK CBD industry. Don’t miss out on this interesting debate. If you […]
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.
Free sample available
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.